Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director comp.
Acq. announced
Appointed director
Ocuphire Pharma, Inc. (OCUP) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/11/2023 8-K Quarterly results
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/01/2023 8-K Quarterly results
06/02/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Third Amendment to Second Amended and Restated Bylaws of Ocuphire Pharma, Inc"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Investor presentation, Quarterly results
Docs: "End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis Set for September 28, 2023; Nyxol Development and Commercialization Funded by Viatris",
"Corporate Presentation"
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/21/2023 8-K Quarterly results
04/05/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2023 8-K Quarterly results
02/14/2023 SC 13G/A Sooch Mina reports a 5.5% stake in Ocuphire Pharma, Inc.
02/14/2023 5 Sooch Mina (President and CEO) has filed a Form 5 on Ocuphire Pharma, Inc.
02/14/2023 5 Ainsworth Sean (Director) has filed a Form 5 on Ocuphire Pharma, Inc.
01/25/2023 8-K Investor presentation
Docs: "Investor Presentation Materials",
"[email protected]"
12/06/2022 8-K Quarterly results
11/07/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "License and Collaboration Agreement by and between Ocuphire Pharma, Inc. and Famy",
"Conference Call Tomorrow November 8, 2022 at 8:30 AM ET"
11/04/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/04/2022 8-K Quarterly results
10/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 8-K Investor presentation, Quarterly results
Docs: "Positive Results from Phase 3 LYNX-1 Trial of Nyxol in Night Vision Disturbances Mark Sixth Positive Nyxol Clinical Data Readout Across Multiple Indications Data Expected in 2H 2022 from Phase 2b Trial of APX3330, a Potential First-in-Class Oral Treatment for Diabetic Retinopathy",
"Corporate Presentation"
06/17/2022 8-K Quarterly results
06/10/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/10/2022 8-K Quarterly results
06/02/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/19/2022 8-K Quarterly results
05/17/2022 SC 13G Richmond Brothers, Inc. reports a 6.2% stake in Ocuphire Pharma, Inc.
05/13/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/13/2022 8-K Quarterly results
04/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ocuphire Completes Last Clinical Trial Supporting the Planned 2022ndA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol ® for Reversal of Mydriasis"
04/27/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy